Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Alkermes (ALKS) reported mixed Q2 2025 results, with overall revenue of $390.66 million and EPS of $0.52 both declining year-over-year, yet significantly surpassing Wall Street consensus estimates by 15.38% and 26.83% respectively. While manufacturing and royalty revenues saw a notable 35.8% year-over-year decrease, product sales, net, surged 14.1% to $307.24 million, driven by strong performance from proprietary drugs like ARISTADA (+17.8%) and LYBALVI (+18.1%), all of which also exceeded analyst projections. Despite these estimate beats, ALKS shares have declined 8.6% over the past month, underperforming the S&P 500.

Analysis

Alkermes reported a mixed financial picture for Q2 2025, with headline figures showing a year-over-year decline in both total revenue, which fell 2.1% to $390.66 million, and EPS, which dropped to $0.52 from $0.72. However, these results significantly surpassed Wall Street expectations, with revenue beating the consensus estimate by 15.38% and EPS delivering a positive surprise of 26.83%. The divergence in performance is rooted in the company's revenue streams; while Manufacturing and Royalty revenues experienced a sharp 35.8% year-over-year contraction, this was offset by robust growth in the core business. Net product sales climbed 14.1% YoY to $307.24 million, driven by strong performance across its proprietary drug portfolio, including ARISTADA (+17.8% YoY), LYBALVI (+18.1% YoY), and VIVITROL (+8.8% YoY), all of which also exceeded analyst projections. Despite the strong operational beat, the company's stock has underperformed, returning -8.6% over the past month against the S&P 500's +3.6% gain, suggesting the market may be weighing the headline declines and royalty weakness more heavily than the underlying product sales momentum.

Key Decisions for Investors

• Investors should look past the headline year-over-year declines and focus on the operational strength in the proprietary product portfolio, where key drugs showed double-digit growth and significantly beat analyst forecasts.
• It is critical to assess the sustainability of the 35.8% drop in manufacturing and royalty revenues, as this segment's weakness is currently masking the underlying health and growth of the core product sales business.
• The stock's recent -8.6% underperformance, despite a substantial earnings beat, warrants evaluation as a potential market overreaction, possibly creating a buying opportunity if the core product growth trajectory is sustainable.